论文部分内容阅读
按韦飞燕的说法,她一直在坚持“做对的事和用对的方式去做事”。一方面,花红药业会继续深耕中国女性大健康市场,另一方面,韦飞燕已经在围绕海上丝绸之路布局。去年花红药业在越南的销售状况很好,年利润达500万元,它还准备进入老挝、缅甸、泰国市场。韦飞燕是全国人大代表,她在今年两会语出惊人:“90%以上的药品都有降价空间,价格砍掉50%一点问题都没有。”从事制药工作30多年的韦飞燕坦
By Wei Feiyan’s argument, she has been insisting “doing right thing and using right way ”. On the one hand, the bonus medicine industry will continue to cultivate the Chinese women’s health market. On the other hand, Wei Feiyan has already laid out the layout around the maritime Silk Road. Last year, the pharmaceutical sales in Vietnam were in good condition with an annual profit of 5 million yuan. It is also preparing to enter the markets of Laos, Myanmar and Thailand. Wei Feiyan, a NPC deputy, said she was surprised at the two sessions this year: “More than 90% of the medicines have room to cut prices and 50% of the prices have been cut off.” "Wei Fei Yan Tan, who has been in the pharmaceutical industry for over 30 years,